Sanofi (France) (SAN.PA)'s Genzyme Corporation (GENZ) to Present New Data From AUBAGIO® and LEMTRADA™ Clinical Development Programs at ECTRIMS  
10/9/2012 11:15:03 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today new data from Genzyme’s clinical development programs for AUBAGIO® (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.